News
There is always something going on at Lipotype:
find the latest news and press releases here
-
What does “GCP-compliant” mean for a bioanalytical laboratory?
GCP (Good Clinical Practice) is not a certification but an inspectable state of readiness demonstrated through quality systems, documented procedures, trained personnel, and comprehensive audit trails. For Lipotype, it means our analytical workflows, documentation, and quality management system are aligned with ICH E6(R3) and the EMA GCLP Reflection Paper (EMA/INS/GCP/532137/2010), so data we generate is traceable, audit-ready, and suitable for integration into a regulatory submission.
-
Is Lipotype GCP-certified?
No – and that distinction matters. GCP compliance is an inspectable state, not a certifiable standard. Lipotype should not be described as “GCP-certified.” The correct terminology is “GCP-aligned,” “GCP-compliant,” or “inspection-ready.”
-
What is ALCOA++ and how does Lipotype implement it?
ALCOA++ is the data integrity framework requiring that all records be Attributable, Legible, Contemporaneous, Original, and Accurate – plus Complete, Consistent, Enduring, and Available. During GCP analysis, every action at Lipotype is recorded contemporaneously and traceably in accordance with these principles, including sample chain of custody, instrument logs, QC batch records, and deviation documentation.
-
What documents need to be in place before a GCP project can begin?
Signed contractual document including a Quality Agreement (QA), Data Transfer Agreement (DTA), Study Analysis Protocol (SAP), must all be executed before analysis starts.
-
What is the Study Analysis Protocol (SAP) and who approves it?
The SAP is a sponsor-agreed analytical plan that governs all aspects of the study – methods, acceptance criteria, QC strategy, and deviation handling. It must be reviewed and signed by both parties before any samples are analyzed. Any deviation from the SAP during the study is a formal event requiring documentation and Quality Management sign-off in GCP compliant tier.
-
Does Lipotype offer method validation, and to what standard?
Yes – both partial and full method validation per ICH M10. Validation is documented in a Method Validation Plan (MVP) and results are reported in a Bioanalytical Report (BAR). Method validation is available as a standalone module or as part of a full GCP-compliant bioanalytical package.
-
Can Lipotype deliver data in CDISC SDTM format?
Yes. CDISC SDTM-formatted data transfer is available as a module within the Data Transfer Agreement, alongside a simple format option and a customized format. CDISC SDTM format is typically required for regulatory submissions to the FDA.
-
How long does Lipotype archive data from GCP projects?
Data, QC records, and the final Bioanalytical Report are archived for a minimum of 25 years under controlled access for regulatory-grade projects. This is a genuine long-term operational commitment reflected in project pricing and contract structures.
-
Our project started as RUO – can we upgrade it to full GCP compliance?
No. Data generated under RUO conditions cannot be retrospectively reclassified as GCP/GCLP-compliant. If the regulatory intent of a study changes, the bioanalytical work must be restarted under a properly controlled framework from sample receipt onward.This is a common and avoidable situation. Lipotype addresses it proactively by completing a regulatory tier assessment with every new customer before project initiation – ensuring the right quality framework is in place from day…
-
Can the scope of an ongoing GCP study be changed?
Any expansion to an ongoing GCP study constitutes a protocol amendment and requires formal QM approval. This is handled through a -formal change request. This protects data integrity and ensures traceability of the analytical record.
